ATN class | Number of patients (% of total) | Age range (median; Q1–Q3) | Sex male/female (% male) | Median MMSE at baseline | |||
---|---|---|---|---|---|---|---|
A. Based on thresholds of 798 pg/mL for Aβ42, 87 pg/mL for p181-tau, and 465 pg/mL for t-tau | |||||||
A−/T−/N− | 73 | (32.02%) | 47–83 | (67; 59–72) | 41/32 | (56.16%) | 26 |
A+/T−/N− | 76 | (33.33%) | 49–85 | (66.5; 60–72) | 39/37 | (51.32%) | 25.5 |
A+/T+/N+ | 39 | (17.11%) | 51–83 | (69; 65–74.5) | 20/19 | (51.28%) | 23 |
A+/T−/N+ | 27 | (11.84%) | 50–80 | (68; 64–73) | 11/16 | (40.74%) | 22 |
A−/T−/N+ | 10 | (4.39%) | 56–83 | (64.5; 59.75–66) | 7/3 | (70%) | 26 |
A−/T+/N+ | 3 | (1.32%) | 66–74 | (71; 68.5–72.5) | 1/2 | (33.33%) | 22 |
A−/T+/N− | 0 | (0%) | NA | NA | NA | ||
A+/T+/N− | 0 | (0%) | NA | NA | NA | ||
Total | 228 | 47–85 | (66; 60–72.25) | 119/109 | (52.19%) | 25 | |
B. Based on thresholds of 798 pg/mL for Aβ42, 58.9 pg/mL for p181-tau, and 354 pg/mL for t-tau | |||||||
A−/T−/N− | 63 | (27.63%) | 47–83 | (65; 58–72) | 39/24 | (61.90%) | 25 |
A+/T−/N− | 57 | (25.00%) | 49–85 | (65; 60–72) | 30/27 | (52.63%) | 26 |
A+/T+/N+ | 63 | (27.63%) | 51–83 | (69; 64.5–74) | 28/35 | (44.44%) | 26 |
A+/T−/N+ | 20 | (8.77%) | 50–79 | (68.5; 60–72.5) | 11/9 | (55.00%) | 23 |
A−/T−/N+ | 5 | (2.19%) | 66–76 | (72; 67–72) | 0/5 | (0%) | 27 |
A−/T+/N+ | 14 | (6.14%) | 56–83 | (65.5; 62.5–67.75) | 9/5 | (64.29%) | 26 |
A−/T+/N− | 4 | (1.75%) | 61–74 | (69.5; 65.5–72.5) | 1/3 | (25.00%) | 26 |
A+/T+/N− | 2 | (0.88%) | 75–78 | (76.5;75.75–77.25) | 1/1 | (50.00%) | 26 |
Total | 228 | 47–85 | (66; 60–72.25) | 119/109 | (52.19%) | 25 |